Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Here are three reasons to buy Vertex Pharmaceuticals stock like there's no tomorrow. I can't think of many companies with a more resilient business than Vertex. The drugmaker should be able to ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

The revised Annual Report is be and is hereby submitted for the typographical errors as mentioned in the covering letter annexed to the disclosure.

Vertex Energy Inc (VTNR) stock saw a modest uptick, ending the day at $0.33 which represents a slight increase of $0.01 or 3.13% from the prior close of $0.32. The stock opened at $0.33 and touched a ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

India's semiconductor sector, despite being home to 20-25 per cent of the global design talent, has historically lacked a ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.